Royalty Pharma Says Elan Offer May Lapse Over Buyback

Royalty Pharma said Elan Corp. (ELN) shareholders may approve a share repurchasing program at their meeting on June 17, which would force Royalty to withdraw its $6.7 billion offer to take over the Irish company.

“Royalty Pharma believes that this proposal can still be voted down if a few shareholders change their vote,” Royalty Pharma said today in a statement. “Royalty Pharma remains in active dialogue with Elan shareholders.”

Holders of more than 70 percent of Elan’s American depositary shares had voted on Elan’s four proposals as of 5:30 p.m. New York time yesterday, Royalty Pharma said. Elan’s board rejected Royalty’s latest offer June 10.

Elan shares fell as much as 9 percent in Dublin trading, and were down 5.2 percent as of 1:08 p.m.

To contact the reporter on this story: Kristen Hallam in London at khallam@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.